Introduction: The incidence of clinical prostate cancer in the Arab population is among the lowest in the world. High serum IGF-1 level has been implicated as a possible risk factor for the development of prostate cancer in Caucasians. The purpose of this study was to determine serum IGF-1 and IGFBP-3 levels in healthy Arab men and in Arab men with newly diagnosed benign prostatic hyperplasia (BPH) and prostate cancer, and to compare these values with values reported in Caucasians. Patients and Methods: Subjects were recruited in two groups: (a) indigenous, healthy Arab men aged 15-90 y (n ¼ 383); (b) Arab men with newly diagnosed prostate cancer (n ¼ 30) or BPH (n ¼ 40). Blood was obtained from fasting patients and volunteers, between 8:00 a.m. and 12:00 noon. The serum concentrations of IGF-1 and IGFBP-3 were determined using Immunoradiometric assay (IRMA) kits. Results: As in Caucasians, serum IGF-1 and IGFBP-3 levels declined with age in Arab men. The mean7s.d. of serum IGF-1 levels in healthy Arab men in the age group 15-20, 51-60, 61-70 y were lower (376.27153.2, 134.97105.7 and 89.6748.4 ng/ml, respectively), compared to values reported for similarly aged Caucasians. Arab men with newly diagnosed prostate cancer had significantly higher serum IGF-1 level (Po0.01) and lower IGFBP-3 levels (Po0.01) compared to age-matched Arabs without the disease. Conclusions: Arab men have lower serum IGF-1 levels compared to Caucasians and this may be an important factor in the explanation of the low incidence of prostate cancer in the Arab population.
Introduction
The incidence of clinical prostate cancer in the Arab population as in other Asian population groups is among the lowest in the world (Figure 1 ), for reasons that are not clear. 1 Insulin-like growth factor 1 (IGF-1) has been shown to be an important mitogenic and antiapoptotic peptide in many tumours. 2 It affects the proliferation of normal and malignant cells through both endocrine and paracrine actions. Studies have shown that human prostate cancer cell lines demonstrate an increase in functional IGF-1. 3 As a result of the presence of IGF-1 in prostate cells, and its potential role in the growth and development of prostate cancer, numerous studies have been conducted to find out if serum IGF-1 level may be useful in the diagnosis and management of patients with prostate cancer. The results, to date, have not been conclusive. Some studies (mostly prospective or meta analyses) show increased risk for prostate cancer with increasing IGF levels, [4] [5] [6] [7] [8] while others (mostly nonprospective, small number of patients, etc) have found no relationship between serum IGF-1 and risk for prostate cancer. [9] [10] [11] [12] Since IGF itself is influenced by many other factors, to assess its role accurately in prostate carcinogenesis, a number of authors have looked at serum IGF-1 as well as IGF-binding protein 3 (IGFBP-3)-one of its binding proteins. These investigators have found that high IGF-1 and low IGFBP3 indicate high risk for development of prostate cancer. 4, [13] [14] [15] [16] These findings may have an important role to play in the chemoprevention of prostate cancer. For example, a family member of a patient with prostate cancer found to have higher than usual serum IGF-1 may be advised to start therapy designed to reduce the levels. 2, 4, 17, 18 Furthermore, plasma IGFBP-3 levels are reported to be highest in healthy subjects, followed by patients with localized prostate cancer, while levels are lowest in those with skeletal metastases. 8, 15 Most of the previous epidemiological studies on IGF1 and IGFBP3 (except that by Chokkalingam et al 7 conducted on the Chinese) were in Caucasians with known high risk for prostate cancer. To further understand the role of IGFs in prostate cancer, its study in a community with low incidence of prostate cancer as in Arabs is warranted. The purpose of this study was to determine serum IGF-1 and IGFBP-3 levels in apparently, healthy Arab men as well as in Arab men with newly diagnosed prostate cancer and BPH and to compare the values with those reported in Caucasians.
Subjects and methods
Venous blood was taken from apparently healthy Arab men (Kuwaitis and Omanis) aged 15 to 90 y. The majority of these were healthy blood donors. Blood was also taken from a similar group of Arab men with newly diagnosed prostate cancer or newly diagnosed benign prostate hyperplasia (BPH). Serum concentrations of IGF-1 and IGFBP-3 were determined using immunoradiometric assay (IRMA) kits on an Immulite Machine from Diagnostic Systems Laboratories Inc. (Webster, TX, USA). The values of IGF-1 and IGFBP-3 obtained from healthy Arab men were compared to values already established for apparently healthy normal Caucasians in the USA as contained in the manufacturer's brochure and as reported previously for Scandinavian subjects. 19 The IGF-1 and IGFBP-3 levels obtained from Arab men with newly diagnosed prostate cancer and BPH were compared with those of age-matched Arab men without prostate cancer or BPH. Normal volunteers or patients older than 50 y had digital rectal examination, PSA estimation and TRUS of prostate to exclude prostate cancer. Prostate cancer diagnosis was based on the finding of high PSA and histological confirmation. BPH diagnosis was based on male patients older than 40 y presenting with symptoms suggestive of bladder outlet obstruction, rectal examination confirming an enlarged benign prostate, maximum flow rate less than 15 ml/s with a minimum voided volume of 200 ml, a TRUS of prostate showing no features suggestive of prostate neoplasm and PSA less than 10 ng/ml. Patients with these features in addition must have prostate volume 425 cm 3 on TRUS to be diagnosed as having BPH. In addition, patients with BPH and prostate cancer had more than 90% performance status to be included in this study. Volunteers and patients found to have grossly deranged liver function tests (low total protein, albumin, high liver enzymes) were excluded from this study. Similarly, young men with serum testosterone above 50 (normal 8-35) nmol/l were excluded from the study.
Statistical analysis
Descriptive statistical methods were applied for the entire study. For parameters with normal distribution (Gaussian), the reference range was mean72s.d., while for those with non-normal distribution (non-Gaussian), the values were log-transformed for analysis and the reference range was 2.5-97.5 percentile. Pearson productÀcorrelation coefficient was calculated to measure the association between serum IGF-1 and IGF-BP3 and age. Normograms potraying the distribution of serum IGF1 and IGFBP3 values as a function of age in healthy Arab men were generated based on the least squares regression models. For all analyses, P-value o0.05 was considered statistically significant.
Results
A total of 383 volunteers were recruited into the study. Of this number, 35 were excluded from analysis because of abnormally high hormone levels (n ¼ 11), grossly deranged liver function tests (n ¼ 21) and previously undiagnosed early prostate cancer (n ¼ 3). Most of those excluded for abnormally high hormone levels (mostly testosterone 450 nmol/l) were young men on testosterone supplements for muscle building. Hence, only 348 Figures 2 and 3 show the regression plots of concentrations vs age for serum IGF-1 and IGFBP-3 in normal healthy Arab men. The figures show progressive decline in both factors with increasing age. Table 2 shows the mean serum IGF-1 in Arab men compared to reported values for Caucasian men (USA) as provided in the kit manufacturer's brochure as well as those reported previously for Scandinavian Caucasian men. 19 Figures 2 and 3 and Tables 1 and 2 also show that, as in Caucasians, serum IGF-1 and IGFBP-3 levels declined with age in Arab men. However, Arab men had significantly lower serum IGF-1 compared to Caucasians in all age groups ( Table 2 ). Figure 4 shows the serum IGF-1 levels for Arab men with prostate cancer compared with those of agematched men without prostate cancer. As shown in Table 1 and Figure 4 , Arab men with good performance status and newly diagnosed prostate cancer had significantly higher serum IGF-1 levels compared to agematched Arabs without the disease ( 1 Po0.01). On the other hand, age-matched Arab men with prostate cancer had lower serum IGFBP-3 ( 2 Po0.001) compared to those without the disease as shown in Table 1 and Figure 5 . The ratio of serum IGF-1/IGFBP-3 was higher in Arab men with prostate cancer compared to those without the disease ( Figure 6 ). Patients with prostate cancer had a IGF-1, IGFBP-3 levels and prostate cancer in Arab men EO Kehinde et al IGF-1 was 3.90 to 542.02 ng/ml compared to kit manufacturer's recommended value of 100-995 ng/ml. Similarly, the calculated reference range for IGFBP3 for Arab men was 87.5-2090.80 ng/ml compared to 900-4500 ng/ml for Caucasians as stipulated by the kit manufacturers. Table 3 shows demographic features, distribution of clinical stage and grade of tumours of patients with prostate cancer recruited for this study. An indirect evidence of the rarity of prostate cancer in our centre was the fact that it took us about 3 y before we could find the 30 patients with the disease suitable for inclusion in this study. The population of our catchment area was about 500 000 people.
Discussion
Prostate cancer is one of the most common malignant tumours in Western countries. The aetiology of prostate cancer is currently unknown but it has been suggested that growth factor abnormalities may be involved in initiation and progression of the disease. Studies have shown that IGFs are potent mitogens for a variety of cancer cells including prostate cancer cells since they stimulate cancer cell growth and suppress programmed cell death. 20 The bioavailability of IGFs is modulated by IGFBPs. By binding to IGFs, IGFBPs limit the availability of free IGFs, which are available to activate the type 1 IGF receptor, the principal mediator of IGF regulatory effects. [21] [22] [23] [24] [25] [26] Five recent epidemiological studies, three retrospective 5, 7, 17 and two prospective, 4,27 conducted in Greece, Sweden, China and the United States revealed that circulating levels of IGF-1 are associated with prostate cancer risk, despite differences in laboratory methods (RIA, immunoradiometric assay, and ELISA) and biological specimens used (serum versus plasma). In two of the four studies assessing levels of IGFBP-3 4, 7 there was an inverse association with prostate cancer risk. In contrast, in the only study of IGFBP-1 levels, there was a positive association with prostate cancer risk. 28 IGF-II was associated with prostate cancer risk in one study 27 but not in another. 4 In this study, we found that the levels of IGF-1 and IGFBP-3 in normal healthy Arab males reached a peak at about puberty and declined gradually with age as in Caucasians. 19 However, the levels in the Arab population were significantly lower compared to Caucasians for each age group. Similar low levels of IGF-1 and IGFBP-3 have been reported in the Chinese, also a population with a low incidence of prostate cancer. 7 It is therefore possible that genetic differences in tissue IGF-1 expression may contribute to the differences in incidence of prostate cancer between different racial groups. 29, 30 With respect to serum IGF-1 level and risk of prostate cancer, in this study, we found a strong association between high IGF-1 levels and prostate cancer risk as has been found in the Chinese 7 and in some studies in Caucasians from Greece, Sweden and the USA. 5, 17, 27 Arab men with newly diagnosed prostate cancer had significantly higher serum IGF-1 levels compared to those without the disease (Po0.001). Interestingly enough, in this series, elderly men with BPH had higher serum IGF-1 level compared to patients with prostate cancer and age-matched controls without either disease. In other studies, men with prostate cancer were said to have higher serum IGF-1 levels compared to men with BPH or aged-matched normal men. [31] [32] [33] A possible explanation for the disparity in our study may be because men with prostate cancer in this study were about a decade older than those with BPH. Serum IGF-1 level declines with age.
As was found in other ethnic groups, Arab men with prostate cancer in this study had lower mean serum IGFBP-3 (783.4737.18) compared to age matched men without the disease (897.2744.72 ng/ml) even though the differences are not statistically significant. Our results for IGFBP-3 support those of the study by Chan et al, 4 in which they found a borderline significant inverse trend after adjusting for age and circulating IGF-1, and are consistent with laboratory evidence of an IGF-independent effect of IGFBP-3 on cell growth. 25 Biologically, it is unclear whether the effect of IGFBP-3 is independent of total or free IGF-1. Future studies should evaluate the IGFBP-3 association in conjunction with free IGF-1, for which an assay has only recently been developed and which has not yet been incorporated into epidemiological studies. 7 Many unanswered questions remain regarding serum IGF-1 and IGFBP-3 levels and risk of prostate cancer. [31] [32] [33] For example, Kanety et al 32 actually demonstrated lower serum IGF-1 concentrations in patients with prostate cancer; however, their population was composed mainly of patients with advanced disease, who therefore may have had diminished nutritional status leading to lower 35 reported that plasma IGFBP-3 levels were found to be highest in healthy subjects, followed by patients with localized prostate cancer and patients with lymph node metastases while the lowest levels were found in patients with skeletal metastases. The findings from the Arab population with a low incidence of prostate cancer are in agreement with those of Shariat et al 2002. 35 Taken together, the pathophysiologic significance of these findings remains unclear; however, they suggest that IGFBP-2 and IGFBP-3 levels in serum may be used as prognostic indicators.
Finally, it is possible that part of the reasons for the conflicts in the literature regarding serum levels of IGF-1 and IGFBP-3 levels and prostate cancer risk may be with inappropriate patient selection and the type of specimens analysed. Our analysis excluded men with prostate cancer or BPH with marked reduction of performance status due to either disease or other co-morbid conditions. Poor nutritional status, low serum total protein or albumin affects serum IGF-1 and IGFBP-3 levels. 36 Most studies that corrected for these factors have found a positive association between prostate cancer risk and high IGF-1 and low IGFBP-3 levels. [37] [38] [39] Furthermore, like Li et al, 37 we found that a high IGF-1 to IGFBP-3 molar ratio was associated with an increased risk or prostate cancer ( Figure 6 ). Plasma levels of IGF-1 and IGFBP-3 are also reported to be more reliable than serum levels. 38 Correcting for these factors in future studies by looking at the association between IGFs, their binding proteins and prostate cancer risk might therefore be necessary to establish beyond any reasonable doubts the true association between these factors.
There is now sufficient evidence that the 'Western' diet, rich in protein and animal fat but low in fibre, is contributing substantially to the high incidence of prostate cancer in most developed countries. Circulating total IGF-1 levels are regulated by nutritional and genetic factors. 36 Until recently, the Arabian diet consisted of high levels of fibre and low levels of animal fat and protein. 40 However, this is changing owing to the abrupt rise in purchasing power and the diet is increasingly similar to that in the West. 41, 42 Therefore, the low levels of serum IGF-1 and IGFBP-3 found in the Arabs in this study is unlikely to be due to lower energy and/or protein deprivation.
Conclusion
Healthy Arab men have significantly lower serum IGF-1 and IGFBP-3 levels compared to healthy Caucasians and this may be a possible explanation for the low incidence of prostate cancer in the Arab population. The reasons for this are not clear and more research is needed to elucidate the mechanism involved as this may be of importance in chemoprevention of prostate cancer.
Our study of prostate cancer patients conducted in a low-risk population (Arab men) revealed that serum IGF-1 and IGFBP-3 levels may be associated with prostate cancer risk. Our findings, together with epidemiological studies conducted in high-risk Western populations, provide strong evidence of a possible role for IGFs in prostate cancer. Future investigations should include prospective studies of men from ethnic groups at varying risk of prostate cancer. In addition, epidemiological and laboratory studies are needed to elucidate underlying mechanisms, including the role played by IGF receptor, circulating androgens and free IGF-1, and IGF bioactivity levels within prostatic tissue.
